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Objective: There is a growing interest in evaluating the effectiveness of compassion 
interventions for treating psychological disorders. The present study evaluated the 
effectiveness of “attachment-based compassion therapy” (ABCT) in the treatment of 
fibromyalgia (FM), and the role of psychological flexibility as a mediator of improvements.
Methods: A total of 42 patients with FM were randomly assigned to ABCT or relaxation 
(active control group). Both the intervention and control condition were combined with 
treatment as usual (TAU). The primary outcome was functional status (FIQ), and the 
secondary outcomes were clinical severity (CGI-S), pain catastrophizing (PCS), anxiety 
(HADS-A), depression (HADS-D), quality of life (EQ-5D), and psychological flexibility 
(AAQ-II). Differences between the groups were estimated using mixed-effects models, 
and mediation assessments were conducted using path analyses.
results: The ABCT group demonstrated superior outcomes compared to the relaxation 
group, including better FIQ values after treatment (B = −3.01; p = 0.003). Differences 
in FIQ were maintained at 3-month follow-up (B = −3.33; p =  0.001). The absolute 
risk reduction in ABCT compared to relaxation increased by 40.0%, with an NNT = 3 
based on criteria of ≥50% FIQ reduction after treatment. Psychological flexibility had a 
significant mediating effect on improvements.
conclusion: These results suggest that ABCT combined with TAU appears to be effec-
tive in the treatment of FM symptoms.
clinical Trial registration: http://ClinicalTrials.gov, identifier NCT02454244.
Keywords: attachment-based compassion therapy, fibromyalgia, randomized controlled trial, compassion, 
psychological flexibility
inTrODUcTiOn
Fibromyalgia (FM) is a chronic and debilitating rheumatic condition, which includes symptoms 
of chronic pain, fatigue, and other physical and/or psychological issues such as disturbed sleep, 
cognitive problems, and distress (1). It is associated with mental health disorders such as anxiety 
and depression (2). The etiology of FM is complex and unknown and is still being explored. There 
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are contradictory findings on determinants such as autonomic 
dysfunctions, imbalances in neurotransmitters and hormones, 
and external stressful events. The prevalence of FM has been 
estimated to be 2.9% in the European population (3), and its 
negative impact on work productivity and high usage of health-
care resources has been highlighted (4).
While some studies have demonstrated the effectiveness of 
pharmacological treatments using antidepressants for improving 
pain and quality of life in FM patients (5), the maintenance of 
these benefits is questionable. Multicomponent interventions, 
including cognitive-behavioral therapy (CBT), seem to represent 
a more promising approach. CBT, which combines interven-
tions from both cognitive and behavioral therapies, improves 
pain-coping capacity and reduces depressed mood and health 
care-seeking behaviors in FM patients (6, 7). It has been posited 
that (i) the cognitive components of CBT are likely to correspond 
to improvements in cognitive and affective domains, (ii) the 
behavioral components are likely to correspond to improvements 
in physical functioning and behavioral outcomes, and (iii) both 
cognitive and behavioral components assert a role in reducing 
pain intensity (8). However, the absence of clear, maintainable 
effects on the core symptoms of FM do not allow for a defini-
tive statement regarding the effectiveness of this interventional 
approach (6, 9).
Acceptance and commitment therapy (ACT) reflects a “third 
wave” CBT approach that has been shown to improve pain, 
catastrophizing, acceptance, anxiety, depression, well-being, 
and quality of life in FM patients (10, 11). Furthermore, ACT 
has been shown to be cost-effective in comparison to pharma-
cological options, although it has not showed clear benefits in 
terms of the number of participants needed to treat (11). ACT 
is a transdiagnostic psychotherapeutic conglomerate that seems 
to lead to recovery from mental illness through the mediating 
role of psychological flexibility (i.e., the ability to function in the 
present moment without needless defense, or either persisting 
with or changing behavior in the pursuit of goals) (12). It includes 
a values-based activation component supported by the ongoing 
monitoring of present-moment experience and orientation 
toward acceptance, both of which are characteristics of mindful-
ness training (13).
In addition to being a component of ACT, mindfulness has 
also been delivered as a standalone intervention to patients with 
FM where it has been shown to lead to improve pain perception 
and quality of life (14, 15). In addition to increasing perceptual 
distance from distressing somatic and psychological stimuli, it 
has also been suggested that the spiritual aspects of mindfulness 
training can help to reduce core symptomatology (16). However, 
there is currently insufficient evidence supporting the use of 
mindfulness for patients with FM as a monotherapy alone (17).
Compassion is a psychological construct that involves (i) 
recognizing and understanding the universality of suffering, (ii) 
feeling emotionally connected with others’ suffering, (iii) tolerat-
ing uncomfortable feelings aroused as part of remaining open to 
and accepting of others’ suffering, and (iv) being motivated to 
act to alleviate suffering (18). Compassion has been a focus of 
research in recent years with findings indicating that it is associ-
ated with positive emotions (19) and can reduce stress-induced 
immune and behavioral responses (20). Several intervention 
protocols based on compassion have been described and used to 
treat psychological disorders such as anxiety and depression, with 
promising benefits (21). However, to date, such approaches have 
not been used to treat FM. A new protocol of compassion named 
“attachment-based compassion therapy” (ABCT) has recently 
been developed (22). It comprises eight sessions of 2.5 h duration, 
and includes exercises of mindfulness training and compassion 
such as receiving and offering compassion to (i) friends, (ii) 
individuals deemed to be problematic, (iii) unknown individu-
als, and (iv) oneself. ABCT is based on attachment theory (23), 
which provides a framework for understanding the links between 
close relationships and psychopathology. ABCT includes specific 
practices to identify how the parent–child relationship emerged 
in childhood. Where appropriate, it focusses on trying to solve 
possible maladjustments through reconciliation with parents.
aims of the study
The aim of the present study was to examine the effectiveness 
of ABCT in the treatment of FM by exploiting synergies from 
the psychotherapeutic agents active in mindfulness, compassion, 
and the application of attachment theory. A low-intensity therapy 
based on relaxation (REL), which has been shown to improve FM 
symptoms but without clear clinical relevance (24), was deemed 
to be a suitable active control condition. A further aim was to 
assess the possible mediating role of psychological flexibility on 
clinical improvements in FM patients treated using the target 
intervention.
MaTerials anD MeThODs
Design
A randomized controlled trial (RCT) with two treatment arms 
and a pre-, post-, and 3-month follow-up assessment was con-
ducted. Adults suffering from FM were allocated to the REL or 
ABCT group using parallel assignment and a computer-gener-
ated randomization list. Findings from a third treatment arm 
outlined in the protocol (https://ClinicalTrials.gov Registration 
NCT02454244) that used mindfulness plus amygdala retraining 
are to be reported elsewhere.
Participants
Fibromyalgia patients were recruited from primary health-care 
centres in Zaragoza, Spain. The inclusion criteria were: (1) male or 
female aged between 18 and 65 years, (2) able to read and under-
stand Spanish, and (3) diagnosed with FM by a rheumatologist 
working for the Spanish National Health Service (SNHS). The 
exclusion criteria were: (1) aged <18 or >65 years, (2) presence 
of a severe Axis I psychiatric disorder (dementia, schizophrenia, 
paranoid disorder, alcohol, and/or drug use disorder) or severe 
somatic disorder that from the clinician’s point of view prevented 
the patient from effectively completing a psychological assess-
ment, or (3) concurrent participation in another clinical trial. 
Antidepressant medication use was not considered to be an exclu-
sion criterion so long as the participant agreed not to modify the 
pharmacological treatment that was prescribed during the study 
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period (it was established that the treatment could be decreased 
but not increased).
Participants were recruited from January to March 2015. 
General practitioners (GPs) identified potential participants 
who were then interviewed at the same clinic by an independ-
ent researcher until the required sample size was achieved. This 
researcher assessed suitability according to the inclusion/exclu-
sion criteria and provided potential participants with a general 
overview of the study. Participants were also informed of the 
confidentiality protocol and that they could withdraw from the 
study at any time without effecting the quality of the treatment 
administered by their GP. Witten informed consent was obtained 
from all study participants before assessment, which occurred 
from February to April 2015. The subsequent randomization 
occurred in April 2015 and the intervention was delivered from 
May to October 2015.
sample size
We based our sample size estimation on an expected difference 
in the primary outcome [the Fibromyalgia Impact Questionnaire 
(FIQ)] of at least 20%, which represents a clinically relevant 
criterion. A previous descriptive study with the same context as 
the present work found an FIQ mean and SD of 70.8 and 15.2, 
respectively (25). Thus, a difference of 14.6 points across the 
groups was our target (0.95 SDs). Based on a 5% significance 
level and a statistical power of 80% in a two-tailed test, in order 
to detect this difference, we needed 18 participants in each group. 
We expected a maximum dropout rate of approximately 20%, 
so we increased the numbers to reach a total sample size of 42 
participants.
interventions
Attachment-Based Compassion Therapy
This intervention included a compassion training program (22) 
that was adapted for FM patients. The intervention focused on 
augmenting the patient’s ability to be considerate and kind toward 
(i) themselves and their own experience (specifically their experi-
ence of suffering), and (ii) others’ experience of suffering. ABCT 
consists of 8 weekly 2-h sessions followed by three reminder 
monthly sessions. It involves practices of mindfulness and visu-
alizations based on self-compassion and the attachment style that 
was generated in childhood (Table 1). The program includes daily 
homework assignments that take approximately 15–20  min to 
complete. The therapist in this group (MNG) was a psychologist 
who was specifically trained to conduct teacher training in ABCT.
Relaxation Group (REL)
This arm constituted the active control condition. Participants 
received a low-intensity and non-specific intervention based on 
8 weekly 2-h sessions involving several grouped relaxation tech-
niques such as imagery, autogenic training, progressive muscle 
relaxation, and breathing (Table 1). The program includes daily 
homework assignments that take approximately 15–20  min to 
complete. After completing the 8 weekly sessions, participants 
receive a further three monthly sessions as reminders. For 
ethical reasons, following completion of the study, participants 
in this group had the option to receive ABCT. The therapist 
(Marta Puebla-Guedea) was a psychologist trained in relaxation 
techniques.
Procedure
A researcher who had no other involvement in the study generated 
the random allocation sequence to determine group assignment. 
Randomization was implemented via telephone, and the alloca-
tion details were concealed from the other researchers until all 
participants had been assigned. Participants agreed to participate 
prior to randomization and were not informed of group alloca-
tion until after completion of baseline assessments. Likewise, 
participants were not informed of which allocation condition was 
the target intervention. The outcome assessor remained blind as 
to participant allocation. The RCT was conducted according to 
the “Initiative on Methods, Measurement and Pain Assessment 
in Clinical Trials” (IMMPACT) recommendations and the 
“Consolidated Standards of Reporting Trials” (CONSORT) 
guidelines. The study followed the Helsinki Convention norms 
and subsequent modifications, Declaration of Madrid of the 
World Psychiatric Association and Uniform Requirements 
for Manuscripts Submitted to Bio-Medical Journals. The study 
protocol was approved by the ethical review board of the regional 
health authority of Aragon, Spain (PI15/0049; 01/04/2015). The 
study was conducted from January 2015 (start of recruitment) to 
January 2016 (end-of-study assessment).
Each of the study arms were combined with treatment as usual 
(TAU) provided by the SNHS for FM patients. This treatment is 
offered by the corresponding GP and consists of administering 
pregabalin or other drugs for pain as well as antidepressants such 
as duloxetine (or another similar SNRI) if there is a diagnosis of 
depression. TAU can also include pharmacological treatments for 
insomnia and fatigue. Furthermore, GPs may refer the patient to 
a rheumatologist, psychiatrist, and/or other specialist as required. 
Psychological treatment is not provided by the SNHS and phar-
macotherapy is the frontline option (although it is occasionally 
offered in conjunction with non-pharmacological rehabilitative 
techniques).
Measurements
Participants completed a sociodemographic and clinical survey 
based on a paper-and-pencil battery of questionnaires that were 
assessed at baseline, posttreatment (8 weeks after baseline), and 
3-month follow-up. The following sociodemographic information 
was collected: gender, age, marital status (with a partner vs. not 
with a partner), dwelling (own home vs. rent home), education 
level (primary, secondary, university), and employment status 
(unemployed, employed, sick leave/inability).
The Fibromyalgia Impact Questionnaire (FIQ), which has 
been proposed as a primary efficacy end-point measure in FM 
clinical trials, was the primary outcome. It is a self-report ques-
tionnaire that comprises 10 items to measure the health status of 
patients with FM. The first item focusses on patients’ ability to 
perform physical activities. The next two items require patients to 
indicate the number of days in the past week that they felt good 
as well as how many days of work they missed. The remaining 
seven items are measured using the Visual Analog Scale (VAS) 
TaBle 1 | Session outlines for the treatment groups.
sessions relaxationa aBcT
1 Visualizations I Introduction to the different relaxation techniques 
and learning the distinct types and usefulness of 
each one of them. Initiation to guided relaxation 
through visualizations. Imagination of scenes in 
which one feels at peace and able to let go of stress 
and anxiety
Preparing 
compassion
Theoretical aspects of brain evolution, happiness, and suffering. 
Concept of compassion/self-compassion and elimination of mistaken 
beliefs. Participants are instructed in mindfulness practices such as 
breathing, and compassionate body scan. These practices help to 
regulate attention and emphasize compassionate aspects within 
oneself. They are a core element of the program
2 Visualizations II Imagination training. Deepening in guided relaxation 
through visualizations. Knowing the effects that 
this type of relaxation has in the body and mind. 
Learning in which situations it might be useful. Using 
landscape images to achieve states of relaxation
Self-esteem and 
compassion
Mindfulness and compassion. Differences with self-esteem. How 
to manage and cope with fear of compassion. Practices to try to 
connect with affection and compassion with other beings, and to try 
to generate feelings of security toward oneself. It is analyzed whether 
participants have previously developed a mental referent figure in their 
life, to resort to in distressful situations
3 Visualizations III Working with emotions through imagination. One 
visualizes flying in a balloon. Emotional burdens are 
difficult to alleviate, so they are symbolically released 
and thrown down, helping the mind to be free of 
emotions that cause discomfort
Developing my 
compassionate 
world
Action mechanism of compassion. Importance of replacing self-
criticism with self-compassion. Development of a core element of 
compassion such as the figure of secure attachment. Replacing the 
critical voice with a more compassionate and tolerant one. Importance 
of acceptance in life
4 Autogenic 
relaxation I
Autogenic relaxation initiation. Knowing the effects 
this type of relaxation has in the body and mind. 
Imagining a ball of light and heat to aid sensations 
of relaxation
Relationships and 
compassion
Parenting models during childhood. Understanding that relationships 
with parents generate different ways of relating to the world. 
Awareness of the emotional bond developed toward parents during 
childhood, as well as their implications for the emotional functioning 
of adulthood, and the capacity we have to be able to receive affection 
from others
5 Autogenic 
relaxation II
Deepening in autogenic relaxation. Learning in 
which situations it could be useful and how to use it. 
Working on heaviness sensations. Body sweeping, 
especially emphasizing feelings of heaviness and 
relaxation
Working on 
ourselves
Reconstruction of a secure attachment model, modifying our 
relationships with ourselves and with others by compassion. Practices 
to become aware of our own ability to give affection to others and 
ourselves. Reconciliation with parents (where appropriate)
6 Progressive 
relaxation
Initiation to the progressive relaxation. Explanation 
of this technique and the different benefits of it, such 
as learning to locate and address bodily tension. 
Tensing and relaxing the muscles to become aware 
of the different sensations in both states (i.e., tense 
vs. relaxed)
Advanced 
compassion I
Forgiveness and common barriers to compassion. Importance 
of forgiveness toward oneself and others. Forgiveness through 
meditation: (1) asking forgiveness of others, (2) forgiving oneself, (3) 
forgiving others for wrongs received. Values guide activation to reduce 
suffering
7 Breathing I Learning to use breathing exercises. Knowing the 
benefits that this type of relaxation has in the body 
and mind. Deep inspiration and exhalation. Using 
breathing to calm anxiety
Advanced 
compassion II
Envy and the importance of developing an attachment figure based 
on oneself. How to manage difficult relationships. Trying to understand 
other’s suffering in order to develop applied compassion in daily life
8 Breathing II Deepening in breathing exercises and their benefits. 
Learning different techniques and exercises based 
on pulmonary or external deep breathing, and on 
internal or cellular respiration
Transmitting 
compassion toward 
others
Equanimity, a quality fruit of compassion practice. How to maintain 
compassion exercises throughout life. Practices to develop 
equanimity: we are all the same, the fallacy of categories, giving 
gratitude. Maintenance of compassion toward others and ourselves
aRelaxation group.
ABCT, attachment-based compassion therapy.
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and concern ability to work, pain, fatigue, morning tiredness, 
stiffness, anxiety, and depression. The total score is subjected to 
normalization and ranges from 0 to 100, with higher scores indi-
cating greater functional impairment. The current study used a 
Spanish-language-validated version of the FIQ that demonstrates 
good psychometric properties (26).
Based on previous studies (27), we chose the clinical global 
impression as a proxy for the general well-being of FM patients, 
and we selected a number of secondary measures likely to be 
sensitive to the effects of the intervention. These comprised pain 
catastrophizing, anxiety and depressive symptoms, quality of life, 
and psychological flexibility, the latter of which appears to func-
tion as a transdiagnostic mediating factor for mental health and 
medical conditions (10, 28).
The Clinical Global Impression-Severity Scale (CGI-S) is a 
7-point scale that requires the clinician to rate the severity of the 
patient’s illness at the time of assessment relative to the clinician’s 
past experience with patients that have the same diagnosis. Based 
on their clinical experience, the mental illness of a patient is 
assessed in terms of severity as: normal, not at all ill (1); border-
line, mentally ill (2); mildly ill (3); moderately ill (4); markedly ill 
(5); severely ill (6); or extremely ill (7). It is one of the most widely 
used brief assessment tools in psychiatry, and it has been used in 
previous studies of FM (27).
The Pain Catastrophizing Scale (PCS) is a self-report 
questionnaire that measures pain catastrophizing (one of the 
main symptoms in FM) and comprises 13 items relating to 
focusing excessively on pain sensations, magnifying the threat 
value of pain sensations, and perceiving oneself as unable to 
control the intensity of pain. Items are rated in relation to their 
frequency of occurrence on a 5-point scale, from never (0) 
to almost always (4). The PCS total score is computed as the 
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algebraic sum of the ratings for each item, and varies from 0 to 
52. Higher scores reflect a greater degree of pain catastrophiz-
ing. The Spanish version of the PCS, which has demonstrated 
good psychometric properties in FM patients, was used in the 
present study (29).
The Hospital Anxiety and Depression Scale (HADS) is a 
self-report questionnaire that quantifies the severity of anxiety 
and depressive symptoms in community and hospital settings. 
It includes 14 items that are rated on a 4-point Likert-type scale 
and has two independent subscales (HADS-A and HADS-D). 
Each subscale ranges from 0 to 21. Higher scores indicate more 
severe symptoms. This scale is considered to be one of the best 
questionnaires for assessing anxiety and depressive symptoms 
in patients with pain disorders. The Spanish-validated version 
of the HADS, which has good psychometric properties when 
used with Spanish FM patients, was administered in the present 
study (30).
The VAS of the EuroQol (EQ-5D) is a vertical line that is 
similar to a thermometer on which the best and worst possible 
health states are scored 100 or 0, respectively. It is a standard-
ized, non-disease-specific instrument for describing and valuing 
health-related status in terms of quality of life. The Spanish version 
of the EQ-5D is a valid and practical outcome measure in clinical 
research and can discriminate between healthy individuals and 
chronic patients (31).
The Acceptance and Action Questionnaire (AAQ-II) is a 
self-report tool that evaluates psychological flexibility as the (i) 
unwillingness to experience unwanted emotions and thoughts 
and (ii) inability to be in the present moment or use values-
directed actions when experiencing distressing psychological 
events. It consists of seven items and responses are provided 
using a 7-point Likert scale (from 1 = never to 7 = always). The 
final score ranges from 7 to 49, with higher scores indicative of 
lower levels of psychological flexibility. The Spanish version of 
the AAQ-II, which has emerged as a reliable and valid measure 
of psychological flexibility, was used in the present study (32).
statistical analyses
First, we used means and SD, medians, and interquartile 
range, and frequencies and percentages to assess the balance of 
sociodemographic and clinical outcomes across study arms at 
baseline. For pretreatment comparisons, one-way analyses of 
variance for continuous variables, Mann–Whitney U for ordinal 
data, and the Fisher exact probability test for categorical vari-
ables were used.
The primary between-group analysis to assess the treatment 
effect was performed on an intention-to-treat basis with FIQ 
total score as a continuous variable. It involved using linear 
mixed-effects models in which restricted maximum likelihood 
regression (REML) was used to account for the correlation 
between repeated measures for each individual. REML produces 
less biased estimates of variance parameters when using small 
sample sizes or unbalanced data (33). Regression coefficients 
(B) and 95% confidence intervals (95% CI) were calculated for 
the Group ×  Time interaction between groups at posttest and 
3-month follow-up. We reported the effect size (ES) for each 
pairwise comparison, using the pooled pretest SD to weight the 
differences in the pre-post means, and to correct for the popula-
tion estimate (34). The rule of thumb is usually that an ES of 0.20 
is small, 0.50 is medium, and 0.80 is large. Separate models were 
estimated for each of the secondary outcomes using the same 
analytical strategy. Only the total score of each scale was taken 
into account to keep the statistical analyses as parsimonious as 
possible. Sensitivity analyses were conducted to assess the effects 
of missing data and to examine how robust our primary and 
secondary analyses were. After ensuring that the data were miss-
ing at random, missing values were replaced using the baseline 
observation carried forward (BOCF) approach as well as multiple 
imputations based on chained equations.
We differentiated participants into two categories (respond-
ers/non-responders to treatment) using two different cut-off 
criteria: (a) ≥20% reduction in the pre–post FIQ total score and 
(b) ≥50% reduction in the pre-post FIQ total score (35, 36). These 
two classifications were used to calculate the number needed to 
treat (NNT) in the ABCT group compared to the Relaxation 
group. NNT refers to the estimated number of patients who need 
to be treated with the new proposed treatment (i.e., rather than 
the control comparison treatment) for one additional patient 
to benefit. A confidence interval (95% CI) for each NNT was 
calculated. This index allows findings from RCTs to be more 
meaningful to clinicians.
We examined whether the effect of ABCT on primary and 
secondary outcomes at 3-month follow-up was mediated 
through changes in psychological flexibility at posttest. We 
calculated pre–post change scores on the AAQ-II and pre-
follow-up change scores on the rest of the outcomes. Bivariate 
Pearson correlations between changes in AAQ-II and the 
other outcomes were estimated. We explored the direct and 
indirect relationships between the treatment condition (inde-
pendent variable), AAQ-II (mediator), and clinical outcomes 
(dependent variables) using path analysis. The direct paths 
between the treatment condition and clinical outcomes and the 
indirect effect path through AAQ-II were tested in all the path 
analysis models. Participants with missing data were excluded. 
Regression coefficients (B) of bias-corrected bootstrapped 
indirect effects were calculated as well as their SEs and 95% 
CIs. This procedure produces a test that can be applied to small 
samples, overcoming possible problems of asymmetry in the 
distribution of indirect effects (37). Parameters of indirect 
effects were considered statistically significant when the 95% 
CI did not include 0.
A 5% significance level was used in all two-tailed tests and 
Bonferroni’s multiple comparisons criterion (for the primary but 
not secondary outcomes) were applied to balance type I and type 
II errors. All of the analyses were performed using SPSS-19 and 
Stata-12.
resUlTs
Participants’ Flow and compliance
Of the 83 patients who were eligible for screening, 19 patients 
were excluded (Figure 1). The main reasons for exclusion were 
(i) not diagnosed by a rheumatologist (n =  8), (ii) older than 
* Results of the Mindfulness + Insula retraining will be showed elsewhere
Eligible for screening (n=83)
Paents excluded (n=19)
-Did not meet entry criteria (n=13)
-Refused to parcipate (n=6)
Enrolled and randomized (n=64)
Recruitment
ABCT
(n=23)
Relaxaon
(n=19)
Received:
-Eight sessions (n=7), 30.4%
-Seven sessions (n=7), 30.4%
-Six sessions (n=5), 21.7%
-Five sessions (n=2), 8.7%
-Three sessions (n=1), 4.4%
-Two sessions (n=1), 4.4%
Received:
-Eight sessions (n=10), 52.6%
-Seven sessions (n=5), 26.3%
-Six sessions (n=3), 15.8%
-Four sessions (n=1), 5.3%
Assessment completed (n=20)
Dropouts: (n=3), 13.1%
-Paent decision (n=1)
-Lack of efficacy (n=1)
-Adverse effects (n=1) 
Assessment completed (n=16) 
Dropouts: (n=3), 15.8%
-Paent decision (n=1)
-Lack of efficacy (n=2)
Assessment completed (n=20) 
Dropouts: 0
Assessment completed (n=15)
Dropouts: (n=1), (6.3%)
-Paent decision (n=1)
Allocaon
Intervenon
Follow-up 3 months
Mindfulness + 
Insula retraining
(n=22)*
FigUre 1 | Flowchart of participants in the randomized controlled trial.
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65 years (n = 2), and (iii) suffering from a psychiatric disorder 
(schizophrenia; n = 1) or severe medical disorder (lupus; n = 2). 
Six patients refused to participate. Of the 64 participants who 
were eligible and randomly allocated to a group, 23 were assigned 
to ABCT and 19 to Relaxation (22 participants were assigned to 
a mindfulness + amygdala group, whose results will be reported 
elsewhere). The mean percentage of ABCT sessions attended was 
81.5% (SD = 19.90), whereas 90.1% (SD = 13.55) of the Relaxation 
sessions were attended [with no significant differences between 
groups t(40) = 1.60, p = 0.117]. The level of homework accom-
plishment was similar among groups. Specifically, 17 participants 
(85.0%) in the ABCT group and 13 (81.3%) in the Relaxation 
TaBle 2 | Baseline sociodemographic and clinical features of patients by group.a
characteristics  
at baseline
rel  
(n = 19)
aBcT  
(n = 23)
Test statistic p
Sex, female 19 (100) 23 (100) (b) 1.000
Age 52.21 (5.95) 50.83 (8.70) t = 0.56 (40) 0.559
Relationships, with partner 13 (68.4) 18 (78.3) (b) 0.504
Dwelling, own home 17 (89.5) 21 (91.3) (b) 1.000
education
Primary 4 (21.1) 10 (43.5) (b) 0.312
Secondary 8 (42.1) 8 (34.8)
University 7 (36.8) 5 (21.7)
employment
Housework 6 (31.6) 10 (43.5) (b) 0.543
Employed 3 (15.8) 4 (17.4)
Sick leave/inability 5 (26.3) 7 (30.4)
Unemployed 5 (26.3) 2 (8.7)
Fibromyalgia impact
FIQ (0–100) 62.83 (18.41) 68.49 (16.26) t = 1.06 (40) 0.297
clinical severity
CGI-S (1−7) 4.32 (1.16) 4.52 (0.85) t = 0.67 (40) 0.509
Pain catastrophizing
PCS (0−52) 25.00 (10.92) 24.04 (12.10) t = 0.27 (40) 0.791
anxiety and depression
HADS-A (0−21) 11.37 (5.40) 13.65 (4.06) t = 1.56 (40) 0.126
HADS-D (0−21) 8.05 (6.03) 10.09 (3.19) t = 1.33 (26)c 0.197
Perceived health
EQ-5D (0−100) 54.00 (20.19) 47.83 (12.78) t = 1.16 (29)c 0.258
Psychological flexibility
AAQ-II (10−70) 37.32 (13.34) 41.78 (10.33) t = 1.22 (40) 0.229
REL, relaxation; ABCT, attachment-based compassion therapy; FIQ, fibromyalgia 
impact questionnaire; CGI-S, Clinical Global Impression Severity; PCS, pain 
catastrophizing scale; HADS-A, hospital anxiety and depression scale-anxiety; 
HADS-D, hospital anxiety and depression scale-depression; EQ-5D, visual analog scale 
of EuroQol; AAQ-II, acceptance and action questionnaire.
aData are presented as means (SD) or n (%); p, p-value associated with the 
comparison.
bFisher probability test.
cNo equal variances have been assumed.
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(Fisher’s test, p = 0.742) group completed their homework. The 
majority of participants were taking medication during the 
treatment period [ABCT = 20 (100%); Relaxation = 15 (93.8%); 
Fisher’s test, p = 0.444]. The completion rate was high with 36 
(85.7%) and 35 (83.3%) participants completing the posttreat-
ment and the 3-month follow-up assessments, respectively. Seven 
participants dropped out of the study (3 in the ABCT group, 
and 4 in the Relaxation group). Therefore, a total of 20 (87.0%) 
participants in the ABCT, and 15 (78.9%) in the Relaxation group 
completed the study (Fisher’s test, p = 0.682). Only relationship 
status was significantly associated with attrition [missing with 
a partner =  4 (9.3%), missing without a partner =  7 (33.3%); 
Fisher’s test, p = 0.031]. Given that no baseline-level differences 
in other sociodemographic or primary/secondary outcomes were 
observed between completers and non-completers, dropouts 
were considered to be at random.
group Baseline characteristics
There were no significant differences between the groups on any 
sociodemographic or clinical variable at baseline (Table 2). All 
participants were women in their early fifties, living in their own 
home, and with a secondary school level of education. Participants 
were mostly unemployed and in a relationship. The average rating 
was severe on FM impact (FIQ) and markedly ill for the clinical 
global impression (CGI-S). Participants’ anxiety and depres-
sion levels (HADS) were high and their perceived health status 
(EQ-5D) was relatively fair.
Patient Preferences, credibility of 
Therapies, and Quality of interventions
The preferred choice of intervention of each participant was 
evaluated before group allocation. A similar distribution was 
observed among the study arms. More specifically, 8 (42.1%) 
participants in the Relaxation group, and 13 (56.5%) in the 
ABCT condition, had no specific preference (Fisher’s test, 
p =  0.536). The credibility of the therapy was evaluated from 
0 (minimum credibility) to 10 (maximum credibility). Each 
participant assessed the intervention after receiving it, and no 
significant differences were found among groups [Relaxation 
Median =  8 (Q1 =  7/Q3 =  9); ABCT Median =  8 (Q1 =  8/
Q3 = 8); Z = 0.71; p = 0.476]. All sessions were audio recorded 
in every intervention group, and one of the researchers, who was 
a senior therapist (Javier García-Campayo), randomly attended 
and assessed two sessions of each study arm to confirm that the 
psychological treatments followed the corresponding protocol 
with a high level of fidelity.
efficacy in the Primary and secondary 
Outcomes
Table  3 shows the descriptive statistics and between-group 
analyses. There were significant differences in FIQ, with ABCT 
performing better than Relaxation at posttest (B  =  −22.07, 
Z = −3.01, p = 0.003) and at 3-month follow-up (B = −24.78, 
Z = −3.33, p =  0.001), with high ESs (d =  1.33 and d =  1.38, 
respectively). Results involving the secondary outcomes showed 
a similar pattern of differences, except for PCS, which showed 
no significant differences at any time. Models with imputed 
missing values using the BOCF method showed small reductions 
in regression coefficients, but results remained unaltered. The 
chained equations method reinforced significant differences in 
FIQ, HADS-D (at posttest), EQ-5D, and AAQ-II (Table S1 in 
Supplementary Material).
absolute risk reduction and number 
needed to Treat
A total of 75.0% of participants in the ABCT group and 18.8% of 
participants in the Relaxation group [15 of 20 (ABCT) and 3 of 16 
(Relaxation) who completed pre- and post-assessments] reached 
the criterion of ≥20% FIQ reduction after treatment. Therefore, 
the absolute risk reduction in ABCT compared to Relaxation 
increased by 56.3% (95% CI = 29.3–83.2%), with an NNT = 2 
(95% CI = 1.2–3.4%). Furthermore, 40.0 and 0.0% of the partici-
pants in the ABCT and Relaxation groups (8 of 20, and 0 of 16, 
who completed pre- and post-assessments), respectively, reached 
the criterion of ≥50% FIQ reduction after treatment. Therefore, 
the absolute risk reduction in ABCT compared to Relaxation 
TaBle 4 | Indirect effects of AAQ-II (n = 35).
Outcomes B se 95% ci
FIQ −15.98 6.05 −29.52 −5.91
CGI-S −0.13 0.22 −0.56 0.32
PCS −2.76 1.59 −6.72 −0.30
HADS-A −1.76 1.01 −4.14 −0.10
HADS-D −2.79 0.85 −4.82 −1.41
EQ-5D 3.94 4.17 −2.72 14.25
B, regression coefficient of the bootstrapped indirect effect; 95% CI, bias corrected 
confidence interval of indirect effects; FIQ, Fibromyalgia Impact Questionnaire; CGI-S, 
Clinical Global Impression Severity; PCS, Pain Catastrophizing Scale; HADS-A, Hospital 
Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety and Depression 
Scale-Depression; EQ-5D, Visual Analog Scale of EuroQol.
TaBle 3 | Descriptive statistics and between-group analyses with observed data.
Outcomes/time points rel (n = 15) Mn (sD) aBcT (n = 20) Mn (sD) d B (95% ci) Z p
FiQ
Baseline 61.12 (20.21) 68.37 (17.38)
Posttreatment 61.22 (25.90) 43.51 (10.31) 1.33 −22.07 (−36.46 to −7.48) −3.01 0.003
Follow-up 67.82 (17.77) 49.13 (15.07) 1.38 −24.78 (−39.35 to −10.20) −3.33 0.001
cgi-s
Baseline 4.27 (1.28) 4.60 (0.82)
Posttreatment 4.33 (0.82) 3.65 (0.49) 0.96 −1.11 (−1.85 to −0.36) −2.91 0.004
Follow-up 4.07 (0.80) 3.20 (0.70) 1.14 −0.91 (−1.67 to −0.15) −2.35 0.019
Pcs
Baseline 25.93 (10.14) 23.75 (12.79)
Posttreatment 23.47 (14.49) 18.55 (11.94) 0.23 0.17 (−5.93 to 6.26) 0.05 0.957
Follow-up 23.53 (13.58) 18.05 (10.50) 0.28 −1.89 (−8.61 to 4.84) −0.55 0.582
haDs-a
Baseline 11.53 (6.06) 13.95 (4.27)
Posttreatment 10.53 (5.24) 7.65 (2.62) 1.03 −4.62 (−7.12 to −2.12) −3.63 <0.001
Follow-up 9.80 (4.84) 7.60 (2.82) 0.90 −3.08 (−5.63 to −0.53) −2.37 0.017
haDs-D
Baseline 8.33 (6.67) 10.35 (3.28)
Posttreatment 7.53 (4.81) 4.80 (2.84) 0.94 −4.41 (−6.82 to −2.00) −3.59 <0.001
Follow-up 7.80 (5.99) 4.70 (2.00) 1.01 −3.82 (−6.28 to −1.36) −3.04 0.002
eQ-5D
Baseline 53.07 (21.71) 48.25 (13.01)
Posttreatment 56.87 (18.95) 66.65 (10.77) −0.84 18.01 (6.56–29.47) 3.08 0.002
Follow-up 61.67 (15.66) 71.65 (7.34) −0.85 14.83 (3.13–26.53) 2.49 0.013
aaQ-ii
Baseline 38.00 (14.23) 42.35 (10.54)
Posttreatment 39.07 (13.90) 29.50 (6.94) 1.13 −13.04 (−20.53 to −5.55) −3.41 0.001
Follow-up 37.00 (12.78) 26.80 (5.82) 1.18 −14.90 (−22.49 to −7.31) −3.85 <0.001
REL, relaxation; ABCT, attachment-based compassion therapy; Mn, mean; d, Cohen’s d effect size corrected for repeated measures; B, regression coefficient; 95% CI, 95% 
confidence interval; Z, value of the Z statistic; p, p-value for each comparison; FIQ, Fibromyalgia Impact Questionnaire; CGI-S, Clinical Global Impression Severity; PCS, pain 
catastrophizing scale; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety and Depression Scale-Depression; EQ-5D, Visual Analog Scale of 
EuroQol; AAQ-II, Acceptance and Action Questionnaire.
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increased by 40.0% (95% CI = 18.5–61.5%), with an NNT = 3 
(95% CI = 1.6–5.4%).
indirect effects of Psychological Flexibility
There was a significant change from baseline to posttreatment 
in AAQ-II in the ABCT [t(19) = 4.75, p < 0.001] but not in the 
Relaxation [t(15) = −0.57, p = 0.580] condition. Considering the 
total sample, correlations between pre-post changes in AAQ-II 
and pre-follow-up changes in clinical outcomes were significant 
for the FIQ (r = 0.46, p < 0.001), HADS-A (r = 0.51, p < 0.001), 
HADS-D (r = 0.54, p < 0.001), and EQ-5D (r = −0.29, p = 0.037), 
but they were not significant for the CGI-S (r = 0.23, p = 0.094), 
and PCS (r = 0.04, p = 0.778). With the exception of PCS, there 
were significant direct paths between the study condition and 
clinical outcomes. The study condition predicted the change 
in AAQ-II (B = −13.92, p =  0.001), which in turn predicted 
the change in FIQ (B =  1.15, p =  0.001), HADS-A (B =  0.13, 
p = 0.020), and HADS-D (B = 0.20, p < 0.001). The percentage 
of the study condition effect on FIQ mediated through AAQ-II 
was 62.0% [the non-significant direct path (B = 8.19; p = 0.232) 
between the study condition and FIQ accounted for the remain-
ing 38.0%], on HADS-A it was 38.1% [the significant direct path 
(B = −2.86; p = 0.044) between the study condition and HADS-A 
accounted for the remaining 61.9%], and on HADS-D it was 
54.5% [the significant direct path (B = −2.33; p = 0.045) between 
the study condition and HADS-D accounted for the remaining 
45.5%]. These values were not compatible with the idea of full 
mediation. There were not significant direct effects between study 
condition and PCS (−3.30; p = 0.274), but there were significant 
indirect effects through AAQ-II (Table 4).
DiscUssiOn
This is the first study to evaluate the efficacy of ABCT for 
treating FM. ABCT can be considered a “third-generation” 
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protocol because it seeks to foster interpersonal virtues, such 
as compassion, forgiveness, and gratitude (38). The program is 
specifically based on attachment styles, a psychoanalytical con-
cept that describes the relationship children develop with their 
parents and that influences the interpersonal relationships and 
self-image they subsequently develop. Through the awareness 
and clarification of values in the fields of family, friendship, love, 
work, spirituality, and general well-being, ABCT encourages 
a reorientation of the person’s life by the acceptance of his/her 
specific situation, improving activation and functioning in each 
specific context (22).
Attachment-based compassion therapy plus TAU produced 
greater increases in the general health status of FM patients 
(i.e., as measured by the FIQ) compared to a group of relaxation 
practices added to TAU. These improvements were maintained 
in a significant way at 3-month follow-up. Additional significant 
improvements in the ABCT group were also observed in clinical 
severity, anxiety, depression, quality of life, and psychological 
flexibility. Surprisingly, they were not observed in pain catastro-
phizing, a keystone variable of this syndrome, which has been 
reduced in FM patients by more cognitively complex approaches 
such as ACT (10). In general, the ESs obtained in the present 
study were larger than those achieved when treating FM using 
CBT (39) or mindfulness alone (15). For general health status and 
quality of life, ESs were similar to those observed in a previous 
study using ACT, but they were higher for anxiety and depres-
sion and lower for pain catastrophizing (10). The clinical value 
of ABCT in terms of the NNT was apparent, and varied from 2 
to 3 depending on the cut-off point considered. Therefore, ABCT 
might be considered as an effective treatment for reducing FM 
symptoms (40).
Mediation analyses showed that pre–post changes in psycho-
logical flexibility partially mediated the relationships between 
study condition and FM global health status, pain catastrophiz-
ing, anxiety, and depression at follow-up. These results are in line 
with those obtained in other studies examining psychological 
flexibility as a transdiagnostic key factor of psychopathologi-
cal change processes in complex and chronic conditions (41). 
Overcoming the dominance of private experiences over chosen 
values and contingencies in guiding action might be a core ele-
ment underlying psychotherapeutic change (42), and it could be 
related to the values-based activation, acceptance, and persis-
tence that are characteristics of third wave therapies such as ACT 
(10, 12). However, our results suggest that ABCT therapeutic 
processes might also depend on other mediators, given that 
psychological flexibility did not explain all of the improvements. 
In this sense, future research could seek to evaluate the possible 
mediating role of other variables related to the main ingredients of 
ABCT, such as attachment, compassion, and mindfulness facets. 
Notwithstanding this, it is not possible to discard other mecha-
nisms of action operating through psychological flexibility, and it 
would be worth investigating in future research, for instance, the 
extent of the synergistic interplay of this variable (43).
Despite the aforementioned treatment effects, findings should 
be interpreted in light of their limitations. First, although the final 
sample size used was within the limits of our power calculation, 
it was relatively small when considering drop out. Although the 
target was to detect outcome differences with a clear clinical 
meaning, this could lead to findings of no significant differences 
with moderate ESs in some cases. Second, the study did not con-
trol for the possible influences of the therapist and thus it remains 
unknown how therapist variables could have affected the results. 
This limitation could be addressed in future studies by estimating 
the percentage of variance explained by the therapists’ influence. 
Finally, the study did not compare the intervention with other 
psychological treatments that have demonstrated effectiveness for 
FM such as CBT or ACT (9, 10). In this sense, future studies could 
compare the effectiveness and cost-effectiveness of the proposed 
intervention with other active control conditions that are similar 
in terms of duration, allegiance, and expectations, etc. It would 
be also interesting to investigate and separate the active ABCT 
ingredients (among which might be attachment, compassion, 
or mindfulness) in order to investigate how they affect different 
subgroups of FM patients (44, 45).
In terms of the study strengths, it is worth highlighting that 
participants’ preferences, credibility of the therapies, and qual-
ity of the interventions were of a similar distribution between 
groups. Therefore, it was possible to circumvent some of the 
aforementioned limitations without statistical control proce-
dures, which usually involve a loss of power when attempting to 
detect differences using small sample sizes. Moreover, the use of 
two different methods to impute dropouts and the triangulation 
of results using both observational and imputing data procedures 
reinforced the strength of our findings.
The ABCT third-generation intervention, added to TAU, 
proved to be more effective than TAU plus relaxation at posttest and 
3-month follow-up in the treatment of FM patients. Psychological 
flexibility appears to be a mediating treatment factor although it 
remains unclear whether other variables—including those related 
to attachment, compassion, and mindfulness—might also exert 
a mediating role in improving FM symptomatology. Findings 
suggest that studies investigating the cost-effectiveness of ABCT 
for treating FM are warranted.
eThics sTaTeMenT
Participants agreed to participate prior to randomization and 
were not informed of group allocation until after completion of 
baseline assessments. Likewise, participants were not informed 
of which allocation condition was the target intervention. The 
outcome assessor remained blind as to participant alloca-
tion. The RCT was conducted according to the “Initiative on 
Methods, Measurement, and Pain Assessment in Clinical Trials” 
(IMMPACT) recommendations and the “Consolidated Standards 
of Reporting Trials” (CONSORT) guidelines. The study followed 
the Helsinki Convention norms and subsequent modifications, 
Declaration of Madrid of the World Psychiatric Association 
and Uniform Requirements for Manuscripts Submitted to 
Bio-Medical Journals. The study protocol was approved by the 
ethical review board of the regional health authority of Aragon, 
Spain (PI15/0049; 01/04/2015). The study was conducted from 
January 2015 (start of recruitment) to January 2016 (end-of-study 
assessment).
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